Jpmorgan Chase & CO Caribou Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 804,554 shares of CRBU stock, worth $1.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
804,554
Previous 2,495,922 67.77%
Holding current value
$1.84 Million
Previous $3.97 Million 81.55%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$0.88 - $1.88 $1.49 Million - $3.18 Million
-1,691,368 Reduced 67.77%
804,554 $732,000
Q4 2024

Feb 12, 2025
BUY
$1.59 - $2.79 $3.28 Million - $5.75 Million
2,062,563 Added 475.95%
2,495,922 $3.97 Million
Q3 2024

Dec 26, 2024
SELL
$1.56 - $2.73 $47,842 - $83,723
-30,668 Reduced 6.61%
433,359 $845,000
Q3 2024

Nov 08, 2024
SELL
$1.56 - $2.73 $47,842 - $83,723
-30,668 Reduced 6.61%
433,359 $845,000
Q2 2024

Dec 26, 2024
BUY
$1.62 - $5.05 $49,682 - $154,873
30,668 Added 7.08%
464,027 $761,000
Q2 2024

Aug 12, 2024
SELL
$1.62 - $5.05 $137,742 - $429,381
-85,026 Reduced 15.49%
464,027 $761,000
Q1 2024

Dec 26, 2024
BUY
$4.82 - $8.26 $557,645 - $955,632
115,694 Added 26.7%
549,053 $2.82 Million
Q1 2024

May 10, 2024
SELL
$4.82 - $8.26 $134,627 - $230,710
-27,931 Reduced 4.84%
549,053 $2.82 Million
Q4 2023

Dec 26, 2024
BUY
$3.58 - $6.25 $514,177 - $897,656
143,625 Added 33.14%
576,984 $3.31 Million
Q4 2023

Feb 12, 2024
BUY
$3.58 - $6.25 $16,489 - $28,787
4,606 Added 0.8%
576,984 $3.31 Million
Q3 2023

Nov 14, 2023
SELL
$4.08 - $8.14 $80,800 - $161,204
-19,804 Reduced 3.34%
572,378 $2.74 Million
Q2 2023

Aug 11, 2023
SELL
$4.04 - $5.47 $43,615 - $59,054
-10,796 Reduced 1.79%
592,182 $2.52 Million
Q1 2023

May 18, 2023
BUY
$4.3 - $7.78 $184,758 - $334,283
42,967 Added 7.67%
602,978 $3.2 Million
Q1 2023

May 11, 2023
SELL
$4.3 - $7.78 $172,369 - $311,869
-40,086 Reduced 6.68%
560,011 $2.97 Million
Q4 2022

Feb 13, 2023
SELL
$5.57 - $11.01 $6,979 - $13,795
-1,253 Reduced 0.21%
600,097 $3.77 Million
Q3 2022

Nov 14, 2022
BUY
$5.34 - $12.79 $490,115 - $1.17 Million
91,782 Added 18.01%
601,350 $6.34 Million
Q2 2022

Aug 11, 2022
SELL
$5.1 - $9.74 $31,568 - $60,290
-6,190 Reduced 1.2%
509,568 $2.77 Million
Q1 2022

May 11, 2022
BUY
$8.42 - $15.32 $4.19 Million - $7.62 Million
497,692 Added 2754.85%
515,758 $4.74 Million
Q4 2021

Feb 10, 2022
BUY
$14.59 - $23.26 $160,519 - $255,906
11,002 Added 155.75%
18,066 $273,000
Q3 2021

Nov 12, 2021
BUY
$15.75 - $30.29 $111,258 - $213,968
7,064 New
7,064 $169,000

Others Institutions Holding CRBU

# of Institutions
135
Shares Held
43.9M
Call Options Held
25K
Put Options Held
53.2K
View Full List

About Caribou Biosciences, Inc.

CRBU Quotes by TradingView
  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $139M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email